Physician profile
Dympna Coll
NPI 1972531549
$4,934.72
in general payments reported to CMS, 2019-2025
41 companies · $531 in 2025
The $531 reported for 2025 was more than what 80% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $615 · 2020: $280 · 2021: $481 · 2022: $1,045 · 2023: $695 · 2024: $1,287 · 2025: $531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,512.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $506.47 | 2019-2025 | Orilissa, Lo Loestrin Fe, Liletta |
| Amgen INC. | $368.82 | 2019-2024 | Prolia, Evenity |
| Astellas Pharma US INC | $286.71 | 2019-2024 | Veozah |
| Shield Therapeutics INC | $279.49 | 2023-2024 | Accrufer |
| Novo Nordisk INC | $279.34 | 2019-2025 | Wegovy |
| Hologic Sales and Service, LLC | $258.45 | 2019-2025 | Myosure Tissue Removal Device, Aptima, Acessa Provu System |
| Mayne Pharma Commercial LLC | $246.87 | 2021-2025 | |
| Organon LLC | $241.99 | 2021-2025 | Nexplanon |
| Therapeuticsmd, INC. | $193.08 | 2019-2022 | |
| Pfizer INC. | $175.36 | 2019-2024 | |
| Coopersurgical, INC. | $174.54 | 2021-2025 | Paragard T 380a, Paragard T 380a, Sos |
| Agile Therapeutics, INC. | $157.90 | 2022-2024 | Twirla |
| Sumitomo Pharma America, INC. | $131.42 | 2023-2025 | Myfembree, Gemtesa |
| Exeltis, USA INC. | $121.79 | 2024-2025 | Slynd |
| Biogen, INC. | $115.49 | 2024-2025 | Zurzuvae |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dympna Coll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.